

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責，對其準確性或完備性亦無發表聲明，並表明不會就本公佈全部或任何部份內容或因倚賴該等內容而引致之任何損失承擔任何責任。



China Health Group Inc.

中國醫療集團有限公司

(以「萬全醫療集團」名稱在香港經營業務)

(前稱「萬全科技藥業有限公司」)

(於開曼群島註冊成立之有限公司)

(股份代號: 8225)

澄清公告

截至二零二三年六月三十日的六个月中期报告及中期业绩

茲提述中國醫療集團有限公司（「本公司」）於二零二三年八月十四日發佈的中期报告及中期业绩的公告（以下統稱為「公告」）。

本公司謹此澄清，由于文档格式转化、部分数据导入错误等原因，导致公告中的各类表格部分分隔线未完全显示，造成科目与数据不在同一对应水平上，从而影响数据的核对。为便于理解和审查公告，针对具体的问题，本公司逐一做出以下说明，以避免歧义：

- 1、中英文公告第二页，2022 年半年度平均收入指的是，2022 年全年收入之一半。
- 2、英文版公告第四页调整如下：

CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME (UNAUDITED)

For the six months ended 30 June 2023

<i>Unaudited</i>			
<i>Six months ended 30 June</i>			
	2023	2022	
	RMB'000	RMB'000	
Turnover	15,025	30,299	
Cost of sales	(5,339)	(7,662)	
Staff cost	(1,826)	(2,825)	
Other income	18	118	
Administrative expenses	(1,052)	(821)	
Profit from operations	6,826	19,109	
Finance costs	28	8	
Profit before taxation	6,854	19,117	
Income tax	(1,028)	(2,867)	
Profit for the period	5,826	16,250	
Attributable to:			
owners of the Company			
Profit for the period	5,826	16,250	
Earnings per share (cents)			
- basic	0.6	1.63	
- diluted	0.6	1.63	

3、英文版公告第五页调整如下：

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION (UNAUDITED)		
As at 30 June 2023		
	30-Jun-23	31-Dec-22
	RMB'000	RMB'000
Non-current assets		
Property, plant and equipment	2,160	1,399
	<u>2,160</u>	<u>1,399</u>
Current assets		
Financial assets as fair value through profit or loss	3,601	8,010
Contract costs	43,232	32,916
Trade and bills receivables	117,748	117,032
Trade deposit paid	1,000	1,000
Prepayments and other receivables	18,313	14,208
Cash and cash equivalents	4,534	4,060
	<u>188,428</u>	<u>177,226</u>
Current liabilities		
Trade payables, other payables and accrued charges	20,534	13,574
Contract liabilities	924	1,014
Tax payable	21,421	22,154
Bank borrowings	-	-
	<u>42,879</u>	<u>36,742</u>
Net current assets	145,549	140,484
Total assets less current liabilities	147,709	141,883
Net assets	147,709	141,883
Capital and reserves		
Share capital	88,906	88,906
Reserves	58,884	53,416
	<u>147,709</u>	<u>142,322</u>
Non-controlling interests	-	-439
Total equity	147,709	141,883

4、英文版公告第六页调整如下：

CONDENSED CONSOLIDATED CASH FLOW STATEMENT (UNAUDITED)		
For the six months ended 30 June 2023		
	<u>Unaudited</u>	
	Six months ended 30 June	
	2023	2022
	RMB'000	RMB'000
Net cash (used in)/generated from operating activities	1164	716
Net cash used in investing activities	(4,90)	(4,925)
Net cash used in financing activities	(200)	(70)
Net decrease in cash and cash equivalents	474	(4,278)
Cash and cash equivalents at beginning of the period	<u>4,060</u>	<u>11,364</u>
Cash and cash equivalents at end of the period	<u>4,534</u>	<u>7,086</u>

5、英文版公告第七页调整如下：

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (UNAUDITED)

For the six months ended 30 June 2023

	Share capital	Share premium	Share Based payment reserve	Special reserve	Capital reserve	Statutory reserve	Statutory enterprise expansion fund	Retained (losses)/earnings	Total equity
At 1 January 2022	88,906	1,402	2,845	6,039	6,231	23,661	6,986	19,052	155,572
Profit for the period	-	-	-	-	-	-	-	16,249	16,249
Equity settled Share-based transactions									
At 30 June 2022	88,906	1,402	2,845	6,039	6,231	23,661	6,986	35,751	171,821
At 1 January 2023	88,906	1,402	2,845	6,039	6,231	23,661	6,986	3,688	141,883
Profit for the period	-	-	-	-	-	-	-	5,826	5,826
At 30 June 2023	88,906	1,402	2,845	6,039	6,231	23,661	6,986	9,514	147,709

6、英文版公告第九页调整如下：

4. Revenue and segment information

The Company is principally engaged in providing research, development, medical science events and clinical registry. Breakdown of the revenue from all services is as follows:

	Unaudited Three months ended 30 June		Unaudited Six months ended 30 June	
	2023 RMB'000	2022 RMB'000	2023 RMB'000	2022 RMB'000
Provision of post marketing surveillance, real-world study, medical science events, and medical marketing (PMS)	11,024	16,148	15,025	30,299
Total:	11,024	16,148	15,025	30,299

The turnover for the Period decreases 50% compared with the corresponding period of 2022. Moreover, turnover of PMS for the six months ended 30 June 2023 decreased 50% compared with the corresponding period of 2022. During the Period, the turnover of related parties was RMB0, accounting for 0% of the total turnover.

7、英文版公告第十页更正为 These subsidiaries are subject to a preferential tax rate of 15%。

8、英文版公告第十一页调整如下：

9. Trade and bills receivables

An aged analysis of the trade and bills receivables at the end of the reporting period, based on the invoice date and net of allowances, is as follows:

	<u>Unaudited</u> 30 June 2023	Audited 31 December 2022
	RMB'000	RMB'000
Within 180 days	3,690	6,681
181 to 360 days	3,707	3,680
361 to 540 days	3,680	26,697
541 to 720 days	26,697	33,140
721 to 900 days	33,140	23,696
901 to 1080 days	23,696	15,350
over 1080 days	23,138	7,788
	117,748	117,032

9、英文版公告第十二页调整如下：

10. Trade payables, other payables and accrued charges

As of the end of the reporting period, the ageing analysis of trade payables, based on the invoice date, is as follows:

	<u>Unaudited</u> 30 June 2023 RMB'000	Audited 31 June 2022 RMB'000
Within 30 days	3,344	7,024
31 to 90 days	5,666	2,345
91 to 365 days	10,369	1,440
Over 365 days	1,155	715
	20,534	11,524

10、公告第十三页，英文版 China Medical Group. 更正为 China Health Group. 。

11、英文版公告第十四页英文版更正如下：

The Group recorded a profit before taxation of approximately RMB6,854,000 for the Period, representing a decrease of 64.1% from RMB19,117,000 as compared with that of the corresponding period of 2022. Profit for the Period was approximately RMB5,826,000, and in the corresponding period of last year were approximately RMB16,250,000.

12、中文版和英文版公告第二十页调整如下

於本公司股份及相關股份之好倉

姓名	身份	持有權益之股份數目(股本衍生工具除外)	根據實物結算股本衍生工具持有權益之股份數目	股份總數	權益概約百分比(%)
郭夏	實益擁有人	114,701,941	18,150,000	132,851,941	13.35%
	受控制法團權益	590,716,637	-	590,716,637	59.35%
宋雪梅	實益擁有人	6,500	400,000	416,500	0.04%
張麗	實益擁有人	960,000	-	960,000	0.10%
倪彬暉	實益擁有人	100,000	100,000	200,000	0.02%
仇銳	實益擁有人	-	120,000	120,000	0.01%
甄嶺	實益擁有人	-	100,000	100,000	0.01%

Long positions in shares and underlying shares of the Company

Name of Directors	Capacity/ Nature of interests	Number of ordinary shares held/ interested	Number of underlying shares held/ interested pursuant to share options	Total number of shares	Approximate percentage of the total number of issued shares of the Company
GUO Xia	Beneficial owner	114,701,941	18,150,000 (note 2)	132,851,941	13.35%
	Interest in a controlled corporation	590,716,637 (note 1)	-	590,716,637	59.35%
SONG Xuemei	Beneficial owner	6,500	410,000 (note 2)	416,500	0.04%
ZHANG Li	Beneficial owner	960,000	-	960,000	0.10%
NI Binhui	Beneficial owner	100,000	100,000 (note 2)	200,000	0.02%
QIU Rui	Beneficial owner	-	120,000 (note 2)	120,000	0.01%
ZHEN Ling	Beneficial owner	-	100,000 (note 2)	100,000	0.01%

13、中文版公告第二十五页《股票期權計畫期間的股票期權變動詳情表》第五列第一行的时间应由“2023”更正为“2023”。

14、中文版公告 26 页和英文版公告 27 页调整如下：

根據《守則》C.1.6，一般而言，獨立非執行董事應當出席股東大會，對公司股東的意見有全面、公正的了解。根據《守則》F.2.2，董事會應邀請審核委員會、薪酬委員會、提名委員會及任何其他委員會（視何者適用而定）的主席出席。若有關委員會主席未克出席，董事會主席應邀請另一名委員或如其適當委任的代表出席。該人士須在股東周年大會上回答提問。發行人的管理層應確保外聘核數師出席股東周年大會，回答有關審計工作、編製核數師報告及其內容、會計政策以及核數師的獨立性等問題。但由於疫情影響，本公司獨立非執行董事、審核委員會全體成員以及核數師均未出席2023年6月30日的本公司年度股東大會。

Under code provision C.1.6, generally the independent non-executive directors should attend general meetings to gain and develop a balanced understanding of the views of shareholders. Under code provision F.2.2, the chairman of the board should invite the chairmen of the audit, remuneration, nomination and any other committees (as appropriate) to attend. In their absence, the chairman should invite another member of the committee or failing this their duly appointed delegate, to attend. These persons should be available to answer questions at the annual general meeting. An issuer's management should ensure the external auditor attend the annual general meeting to answer questions about the conduct of the audit, the preparation and content of the auditors' report, the accounting policies and auditor independence. However, due to the epidemic, the independent non-executive Directors, all members of the audit committee of the Board (the "Audit Committee") and the auditor of the Company did not attend the annual general meeting of the Company on 30 June 2023.

除上文澄清外，該公告內之所有資料均維持不變。

承董事會命
中國醫療集團有限公司
主席
郭夏

中国香港，二零二三年八月十七日

於本公佈日期，董事會成員包括兩名執行董事，分別為郭夏先生（主席）及宋雪梅博士；一名非執行董事，為張麗女士；及四名獨立非執行董事，分別為仇銳先生、倪彬暉博士、甄嶺先生和郭彤先生。

本公佈載有根據香港聯合交易所有限公司（「聯交所」）GEM 證券上市規則規定須提供有關本公司資料的詳情，董事就本公佈共同及個別承擔全部責任。董事在作出一切合理查詢後確認，就彼等所知及所信，本公佈所載的資料在各重大方面乃準確完整，無誤導或欺詐成份，且概無遺漏任何其他事宜致使本公佈所載任何陳述或本公佈產生誤導。

本公佈將於 GEM 網址 www.hkgem.com 之「最新公司公告」網頁登出，由登出日期起計為期七日，並於本公司網址 www.chgi.net 網頁登出。